Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
153
-
Total 13F shares, excl. options
-
104M
-
Shares change
-
+1.21M
-
Total reported value, excl. options
-
$340M
-
Value change
-
+$3.77M
-
Put/Call ratio
-
1.03
-
Number of buys
-
69
-
Number of sells
-
-54
-
Price
-
$3.27
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2024
180 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2024.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 153 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 104M shares
of 193M outstanding shares and own 53.82% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (22.6M shares), Whitefort Capital Management, LP (13.2M shares), BlackRock, Inc. (12.9M shares), VANGUARD GROUP INC (8.98M shares), Two Seas Capital LP (8.74M shares), STATE STREET CORP (5.03M shares), GEODE CAPITAL MANAGEMENT, LLC (3.48M shares), BlackBarn Capital Partners LP (2.34M shares), Rubric Capital Management LP (1.68M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1.65M shares).
This table shows the top 153 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.